These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30555190)

  • 1. Prescription Drug Use under Medicare Part D: A Linear Model of Nonlinear Budget Sets.
    Abaluck J; Gruber J; Swanson A
    J Public Econ; 2018 Aug; 164():106-138. PubMed ID: 30555190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonlinear pricing in drug benefits and medication use: the case of statin compliance in Medicare Part D.
    Jung K; Feldman R; McBean AM
    Health Serv Res; 2014 Jun; 49(3):910-28. PubMed ID: 24354765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
    Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
    JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
    Raimond VC; Feldman WB; Rome BN; Kesselheim AS
    Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demand for prescription drugs under non-linear pricing in Medicare Part D.
    Jung K; Feldman R; McBean AM
    Int J Health Care Finance Econ; 2014 Mar; 14(1):19-40. PubMed ID: 24214101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.
    Brill JV
    Am J Health Syst Pharm; 2007 Aug; 64(15 Suppl 10):S3-6; quiz S21-S23. PubMed ID: 17646551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries.
    Shih YT; Xu Y; Liu L; Smieliauskas F
    J Clin Oncol; 2017 Aug; 35(22):2482-2489. PubMed ID: 28471711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
    Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
    JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in Prostaglandin Analog Prices Paid for Through Medicare Part D.
    Priluck AZ; Havens SJ
    J Glaucoma; 2019 Jan; 28(1):e17-e20. PubMed ID: 30234751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myopic and Forward Looking Behavior in Branded Oral Anti-Diabetic Medication Consumption: An Example from Medicare Part D.
    Sacks NC; Burgess JF; Cabral HJ; Pizer SD
    Health Econ; 2017 Jun; 26(6):753-764. PubMed ID: 27150938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of prescription drug insurance on health behavior: Evidence from Medicare Part D.
    Asfaw AA
    Health Econ; 2019 Mar; 28(3):403-418. PubMed ID: 30623501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
    Odouard IC; Anderson GF; Alexander GC; Ballreich J
    J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of alternative pricing methods for drugs in California Workers' Compensation System: Fee-schedule pricing.
    Wilson L; Turkistani FA; Huang W; Tran DM; Lin TK
    PLoS One; 2018; 13(5):e0197449. PubMed ID: 29799850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid.
    McCormick N; Wallace ZS; Sacks CA; Hsu J; Choi HK
    Arthritis Rheumatol; 2020 Feb; 72(2):234-241. PubMed ID: 31609057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillation.
    Evans-Molina C; Regan S; Henault LE; Hylek EM; Schwartz GR
    J Am Geriatr Soc; 2007 Jul; 55(7):1038-43. PubMed ID: 17608876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
    Cortese BD; Dusetzina SB; Luckenbaugh AN; Al Hussein Al Awamlh B; Stimson CJ; Barocas DA; Penson DF; Chang SS; Talwar R
    J Clin Oncol; 2023 Oct; 41(29):4664-4668. PubMed ID: 37290029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Competition on Generic Drug Prices.
    Nguyen NX; Sheingold SH; Tarazi W; Bosworth A
    Appl Health Econ Health Policy; 2022 Mar; 20(2):243-253. PubMed ID: 34904207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.